DailyWealth Investment Newsletter  

About DailyWealth Premium Content DailyWealth Archive
DailyWealth Investment Newsletter DailyWealth Contributors DailyWealth Resources DailyWealth Market Window
 
DailyWealth Print Edition Print Edition | Sponsored Link:
True Wealth Login

The Most Exciting Stock Market in the World Right Now
By Tom Dyson
September 4, 2008

"It's like Cuba opens its markets for the first time, except everyone in America is Cuban, and there are one billion of them..."

Yesterday, I had lunch with the chairman and founder of one of Taiwan's largest financial services firms. Let's call him Mr. Cheng. (I can't give his real name... He's too well known in the business world.)

He took me to an expensive French restaurant. We had our own private room. The waitresses would tap lightly on the door before coming in. And then they'd bow to us...

Mr. Cheng says the opportunity in Taiwan stocks is a "one-in-ten-lifetimes opportunity."

Like Cuba, Taiwan is a small island with enormous potential, politically isolated from one of the world's most powerful economies. Investors drool over the prospect of Cuba opening its doors to American investment. They should be drooling over Taiwan...

The island of Taiwan split from China in 1949 following a civil war. But China still claims Taiwan as its territory and threatens to attack Taiwan from time to time. Officially, the two countries remain at war. This political uncertainty creates news headlines and deters investors from buying Taiwan stocks. So much so that Taiwan is the cheapest stock market in the developed world.

My colleague Ian Davis does great work analyzing world stock markets. He's crunched the P/E ratios, the dividend yields, and the price-to-book ratios of all the countries in the Datastream database of international stock indexes.

Tawain's Taipei stock market is on the bottom right now with a dividend yield of 5.4% and a P/E ratio of 11. Not only is Taipei the cheapest market in the world relative to all the other markets, it's also the cheapest market relative to its own historical standards. People just can't stand the thought of investing here.

But most people don't realize commercial relationships between Taiwan and China are booming. Trade between mainland China and Taiwan will probably reach $120 billion this year.

According to the Associated Press, Taiwanese companies have invested more than $120 billion since the early 1990s in mainland businesses. These businesses supply advanced plant and equipment – like high-tech electrical machinery or rare industrial textiles – to the factories and industries of mainland China.

And the political relationship between China and Taiwan is improving. In March, a new president won power in Taiwan. His name is Ma Ying-jeou. Improving relations with China is at the top of Ma's agenda.

For example, the first direct flights between Taiwan and China in 60 years flew in July. Taiwan will allow 3,000 Chinese tourists to visit every day. That's a big deal. According to Goldman Sachs, direct flights and cross-strait tourism may add 60 to 80 basis points to Taiwan's economic growth.

It's still illegal for Chinese investors to invest in Taiwan... and for Taiwanese investors to invest in China. But that's changing, too.

In August 2007, Chinese authorities unveiled a plan for mainland residents to invest in Hong Kong. This was the first time the government had allowed Chinese investors to invest outside Shanghai. The news sent Hong Kong's Hang Seng Index up 55% in 10 weeks.

I think Taiwan could be one of the next markets Chinese authorities open up to mainland investors. If this happens, we should see a similar pop in Taiwan's stock index.

Related Articles

Three Stocks to Double Your Money in the Next Asian Market Bubble

When to Buy My Favorite Asian Stock Market

Taiwan is very cheap right now. Its large public companies hold enormous amounts of cash, so it's a great place to earn dividends... And it's slowly opening itself up to a huge economic power.

Mr. Cheng has made millions and millions from the stock markets. He's as bullish as can be on Taiwan. In my next column, I'll show you another reason to follow his lead.

Good investing,

Tom

Editor's note: Tom Dyson is a regular contributor to DailyWealth, a free investment newsletter focused on the world's best contrarian opportunities. We write with a simple belief in mind: You don't have to take big risks to make big money with your investments.

Sign up today to read more investment ideas from Tom Dyson.

Email a Friend

Delicious
Reddit

Digg

RSS

ONE OF THE FEW UPTRENDS IN THE MARKET RIGHT NOW

"Dead in the water" is the theme of about every sector you can think of right now. Oil, gold, telecom, real estate, retail, and manufacturers are all struggling.

One of the few trends alive and well is the uptrend in health care and drug stocks. And Johnson & Johnson is taking the lead.

As we pointed out a month ago... J&J is like a huge health care "hedge fund." It sells drugs, medical devices, and all kinds of consumer products. Put another way, J&J does everything from Sudafed to scalpels to schizophrenia drugs. (Our colleague Porter Stansberry has been bullish on J&J for several years... You can read his short J&J write-up here.)

The legendary trader Ed Seykota once claimed he could judge an asset by sticking the chart on the wall and looking at it from across the room. If the uptrend was apparent from that far away, it was strong enough to buy. As our three-year chart of J&J shows, the health care and drug rally is one of today's rare "see it from across the room" charts.

Johnson & Johnson

Social Security is actually a relatively small and fixable piece of the entitlement puzzle. Medicare for the old and Medicaid for the poor are the programs that really threaten to swallow up the budget.

The federal deficit, not counting interest payments, could eat up 9% of GDP by 2050 if business continues as usual. According to Brookings Institution economist Henry Aaron, the two big federal health programs account for nearly all of the gap.

The main problem is not the demographic bulge of baby boomers, says Aaron. It's that health-care costs overall, for private payers as well as in Medicare, are growing about 2.5 percentage points faster than the economy every year.

New drugs, procedures and technologies keep upping the ante, even when we aren't sure if they work better than what came before.

– Pat Regnier,
Money Magazine

Johnson & Johnson's second-quarter earnings rose 8%, beating analysts' estimates, as demand for consumer products helped overcome flagging drug sales.

J&J, the world's largest maker of healthcare products, also raised its full-year earnings forecast. Revenue grew 8.7% in the quarter to $16.5 billion, helped partly by converting sales outside the U.S. into weaker dollars, the company said Tuesday. Analysts had expected revenue of $16 billion.

Sales of consumer products such as Listerine mouthwash and Zyrtec allergy pills are immune to the sluggish U.S. economy that will otherwise slow J&J's sales growth for the rest of the year, Chief Financial Officer Dominic Caruso said.

J&J's fundamentals are "not great, but they're OK," said Les Funtleyder, an analyst with Miller Tabak & Co. in New York. "And OK looks pretty good" in this market.

More than half of J&J's revenue came from overseas, passing U.S. sales for the first time in the company's 122-year history, a spokesman said.

– Bloomberg

How to Profit from Fannie's Troubles
September 3, 2008

I Just Toured the World's Largest Construction Site
September 2, 2008

Labor Day - Markets Closed
September 1, 2008

What Happens to My iShares if Their Sponsor Goes Bankrupt?
August 30, 2008

You May Never See this Opportunity Again
August 29, 2008

Home | About DailyWealth | Premium Content | DailyWealth Archive | Contributors
DailyWealth Resources | Research Reports | Privacy Policy

Customer Service: 1-888-261-2693 – Copyright 2008 Stansberry & Associates Investment Research. All Rights Reserved. Protected by copyright laws of the United States and international treaties. This e-letter may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of Stansberry & Associates Investment Research, LLC. 1217 Saint Paul Street, Baltimore MD 21202